Abbott ranked No. 3 on The Fair360, formerly DiversityInc Top 50 Companies for Diversity list in 2022.
When people arrive at the ER for chest pain, doctors run blood tests to look for proteins in the bloodstream that have been released after the heart muscle has been damaged. These proteins, called biomarkers, help doctors diagnose heart attacks.
Concentrations of specific biomarkers — high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro-brain natriuretic peptide (NT-proBNP) — are different in healthy men and healthy women.
The test often excludes transgender individuals, leading to confusion and misdiagnosis.
A new study titled “Distribution of High-Sensitivity Cardiac Troponin and N-Terminal Pro–Brain Natriuretic Peptide in Healthy Transgender People,” measured the cardiac biomarkers in 79 transgender men and 93 transgender women who had been prescribed testosterone or estrogen for more than one year.
The study showed that cardiac biomarkers in transgender men are similar to those of cisgender men, as with transgender women and cisgender women. Sex hormones, not sex assigned at birth, drive the differences.
The researchers measured the biomarkers using several tests, including Abbott’s ARCHITECT STAT High-Sensitivity Troponin I test.
“This study hopefully jumpstarts additional research that will shed even more light on how sex hormones and gender-affirming therapy affect different biomarkers in transgender individuals,” said Alex Carterson, Divisional Vice President of Medical, Scientific and Clinical Affairs at Abbott. “Abbott is committed to diversity and health equity to make sure that all patients are getting the care that they need by empowering their care providers with accurate diagnostic information about their health.”
Read more at abbott.com.
